Skip to content
10-Q

Quarterly Report

PROVECTUS BIOPHARMACEUTICALS, INC. PVCT

0001493152-25-022229

← back to feed
Filed
Nov 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Nov 12, 2025 420.28M sh
Shares Diluted Q3 2025 · Sep 30, 2025 420.28M sh
Shares Diluted Q3 2025 · Sep 30, 2025 420.28M sh
Shares Diluted Q3 2025 · Sep 30, 2024 419.91M sh
Shares Diluted Q3 2025 · Sep 30, 2024 419.65M sh
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$2.46M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$2.37M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $72.48K
Cash And Equivalents Q3 2025 · Sep 30, 2024 $187.46K
Stockholders Equity Q3 2025 · Sep 30, 2025 −$6.15M
Stockholders Equity Q3 2025 · Dec 31, 2024 −$5.96M
Current Liabilities Q3 2025 · Sep 30, 2025 $6.47M
Current Liabilities Q3 2025 · Dec 31, 2024 $6.98M
Total Liabilities Q3 2025 · Sep 30, 2025 $6.59M
Total Liabilities Q3 2025 · Dec 31, 2024 $6.98M
Current Assets Q3 2025 · Sep 30, 2025 $277.99K
Current Assets Q3 2025 · Dec 31, 2024 $976.77K
Total Assets Q3 2025 · Sep 30, 2025 $419.9K
Total Assets Q3 2025 · Dec 31, 2024 $1.01M
Eps Diluted Q3 2025 · Sep 30, 2025 $0.00
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.01
Eps Diluted Q3 2025 · Sep 30, 2024 $0.00
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.01
Eps Basic Q3 2025 · Sep 30, 2025 $0.00
Eps Basic Q3 2025 · Sep 30, 2025 −$0.01
Eps Basic Q3 2025 · Sep 30, 2024 $0.00
Eps Basic Q3 2025 · Sep 30, 2024 −$0.01
Sga Expense Q3 2025 · Sep 30, 2025 $929.75K
Sga Expense Q3 2025 · Sep 30, 2025 $2.88M
Sga Expense Q3 2025 · Sep 30, 2024 $651.49K
Sga Expense Q3 2025 · Sep 30, 2024 $1.36M
Rd Expense Q3 2025 · Sep 30, 2025 $345.86K
Rd Expense Q3 2025 · Sep 30, 2025 $1.63M
Rd Expense Q3 2025 · Sep 30, 2024 $413.99K
Rd Expense Q3 2025 · Sep 30, 2024 $1.44M
Net Income Q3 2025 · Sep 30, 2025 −$1.31M
Net Income Q3 2025 · Sep 30, 2025 −$4.27M
Net Income Q3 2025 · Sep 30, 2024 −$1.01M
Net Income Q3 2025 · Sep 30, 2024 −$2.37M
Operating Income Q3 2025 · Sep 30, 2025 −$1.28M
Operating Income Q3 2025 · Sep 30, 2025 −$4.17M
Operating Income Q3 2025 · Sep 30, 2024 −$955.73K
Operating Income Q3 2025 · Sep 30, 2024 −$2.2M
Revenue Q3 2025 · Sep 30, 2025 $336.11K
Revenue Q3 2025 · Sep 30, 2024 $109.75K
Revenue Q3 2025 · Sep 30, 2024 $602.81K